PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies

  • Cell Res. 2018 Jul;28(7):779-781. doi: 10.1038/s41422-018-0055-1.
Yonghui Sun  1 ,  Xingwang Zhao  2 ,  Ning Ding  3 ,  Hongying Gao  1  2 ,  Yue Wu  1 ,  Yiqing Yang  1 ,  Meng Zhao  2 ,  Jinseok Hwang  2 ,  Yuqin Song  3 ,  Wanli Liu  4 ,  Yu Rao  5
Affiliations
  • 1. MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Tsinghua University, Beijing, 100084, China.
  • 2. MOE Key Laboratory of Protein Sciences, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, School of Life Sciences, Beijing Key Lab for Immunological Research on Chronic Diseases, Tsinghua University, Beijing, 100084, China.
  • 3. Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, No.52 Fucheng Road, Haidian District, Beijing, 100142, China.
  • 4. MOE Key Laboratory of Protein Sciences, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, School of Life Sciences, Beijing Key Lab for Immunological Research on Chronic Diseases, Tsinghua University, Beijing, 100084, China. [email protected].
  • 5. MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Tsinghua University, Beijing, 100084, China. [email protected].
PMID: 29875397 DOI: 10.1038/s41422-018-0055-1
Products